ERBB2 and gastroesophageal junction adenocarcinoma: For instance, the COMPASSION - 15 phase III clinical trial demonstrated that chemotherapy in combination with cadonilimab significantly improved PFS and OS compared to chemotherapy alone in treatment-naïve patients with HER2-negative locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (HR = 0.62) (15).